Calcitriol Injection Rx
Generic Name and Formulations:
Calcitriol 1mcg/mL; soln for IV inj.
Various generic manufacturers
Indications for Calcitriol Injection:
Hypocalcemia in patients on chronic renal dialysis. Secondary hyperparathyroidism.
≥13yrs: Initially 1–2mcg (0.02mcg/kg) 3 times weekly (approx. every other day); usual range: 0.5–4mcg 3 times weekly. May increase by 0.5–1mcg at 2–4 week intervals. Adjust dose based on PTH levels: see full labeling.
<13yrs: not recommended.
Hypercalcemia. Vit. D toxicity.
Avoid concurrent Vit. D therapy. Maintain adequate calcium intake. Keep serum calcium times phosphate (Ca x P) product below 70. Monitor serum calcium and phosphorus twice weekly at start of therapy, and during dose adjustment. Monitor magnesium, alkaline phosphatase, parathyroid hormone levels (PTH) periodically; if PTH levels fall <1.5–3xULN, reduce calcitriol dose or discontinue. Pregnancy (Cat.C). Nursing mothers: not recommended.
Vit. D analog.
Hypermagnesemia with magnesium-containing antacids. Arrhythmias with digitalis if hypercalcemia occurs.
Symptoms of hypervitaminosis D, hypercalcemia, hypercalciuria, hyperphosphatemia.
Formerly known under the brand name Calcijex.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)